American journal of kidney diseases : the official journal of the National Kidney Foundation · 2005
Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dingli David, Larson Dirk R, Plevak Matthew F, Grande Joseph P, Kyle Robert A
Аннотация
BACKGROUND: Focal and segmental glomerulosclerosis (FSGS) is a common histological finding in patients with proteinuria. The natural history of the condition varies, and although it may be responsive to therapy, FSGS is an important cause of end-stage renal disease. FSGS can be caused by a variety of conditions, but it has been reported rarely in association with a plasma cell disorder.
METHODS: Mayo Clinic databases were queried and cross-referenced for FSGS and plasma cell disorders. The diagnoses were confirmed, and relevant clinical and laboratory data were abstracted.
RESULTS: A cohort of 13 patients with "idiopathic" FSGS and a monoclonal plasma cell disorder were identified. Four patients had myeloma, and 9 patients had monoclonal gammopathy of undetermined significance. Patients treated for myeloma experienced improvement in their renal lesion, and the latter relapsed when the myeloma relapsed.
CONCLUSION: We show that FSGS and plasma cell disorders are temporally and epidemiologically linked. Therapy for the underlying plasma cell disorder can lead to resolution of FSGS. The emerging molecular pathogenesis of both FSGS and myeloma also provides potential mechanisms that link the 2 conditions together. Thus, physicians must rule out a plasma cell proliferative disorder in patients with FSGS before concluding that the renal lesion is idiopathic. Moreover, FSGS may respond favorably after the underlying plasma cell disorder is controlled.
METHODS: Mayo Clinic databases were queried and cross-referenced for FSGS and plasma cell disorders. The diagnoses were confirmed, and relevant clinical and laboratory data were abstracted.
RESULTS: A cohort of 13 patients with "idiopathic" FSGS and a monoclonal plasma cell disorder were identified. Four patients had myeloma, and 9 patients had monoclonal gammopathy of undetermined significance. Patients treated for myeloma experienced improvement in their renal lesion, and the latter relapsed when the myeloma relapsed.
CONCLUSION: We show that FSGS and plasma cell disorders are temporally and epidemiologically linked. Therapy for the underlying plasma cell disorder can lead to resolution of FSGS. The emerging molecular pathogenesis of both FSGS and myeloma also provides potential mechanisms that link the 2 conditions together. Thus, physicians must rule out a plasma cell proliferative disorder in patients with FSGS before concluding that the renal lesion is idiopathic. Moreover, FSGS may respond favorably after the underlying plasma cell disorder is controlled.
Предметные рубрики MeSH
AgedAmyloidosisAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBiopsyCohort StudiesCombined Modality TherapyComorbidityCytokinesDatabases, FactualDexamethasoneFemaleGlomerulosclerosis, Focal SegmentalHumansImmunoglobulin Light ChainsKidneyMaleMelphalanMetabolic Clearance RateMiddle AgedMultiple MyelomaMyeloma ProteinsParaneoplastic SyndromesParaproteinemiasPeripheral Blood Stem Cell TransplantationPrednisonePrevalenceProteinuriaRecurrenceRemission InductionRetrospective StudiesTime FactorsVasculitis